Daily Respiratory Research Analysis
Analyzed 114 papers and selected 3 impactful papers.
Summary
Analyzed 114 papers and selected 3 impactful articles.
Selected Articles
1. SIRT5-mediated FDX1 desuccinylation confers cuproptosis resistance in lung adenocarcinoma.
This study identifies a SIRT5–FDX1–TRIM8 axis that destabilizes FDX1 via desuccinylation-triggered ubiquitination, thereby conferring cuproptosis resistance in lung adenocarcinoma. Pharmacologic SIRT5 inhibition synergized with the cuproptosis inducer Elesclomol–Cu to suppress tumor growth in vivo, nominating a combinatorial therapeutic strategy.
Impact: It uncovers a previously unrecognized post-translational mechanism of cuproptosis resistance and offers an actionable combination therapy concept in lung adenocarcinoma.
Clinical Implications: Targeting SIRT5 to stabilize FDX1 may sensitize tumors to copper-dependent cell death; combining SIRT5 inhibitors with Elesclomol–Cu could be explored in early-phase LUAD trials, with biomarkers (FDX1 succinylation/abundance) guiding patient selection.
Key Findings
- Copper stress upregulates SIRT5 and reduces global succinylation in LUAD cells.
- SIRT5 desuccinylates FDX1 at Lys84, triggering TRIM8-mediated ubiquitination and proteasomal degradation.
- SIRT5 inhibitor (MC3482) plus Elesclomol–Cu synergistically suppresses LUAD tumor growth in vivo.
Methodological Strengths
- Mechanistic dissection across post-translational modification, ubiquitination, and proteostasis with in vitro and in vivo validation.
- Therapeutic proof-of-concept with combination efficacy in animal models.
Limitations
- Preclinical models; human clinical validation is lacking.
- Heterogeneity of LUAD and copper handling pathways may affect generalizability and biomarker cutoffs.
Future Directions: Define predictive biomarkers (FDX1 K84 succinylation status, SIRT5 expression) and test SIRT5 inhibitor–cuproptosis inducer combinations in LUAD patient-derived models and early-phase trials.
Cuproptosis, a copper-dependent cell death process induced by excessive copper, represents an emerging therapeutic strategy in oncology. However, tumor-specific molecular pathways regulating this process remain poorly defined. Here, we demonstrate that copper levels are elevated in lung adenocarcinoma (LUAD), and LUAD cell lines exhibit increased resistance to cuproptosis. Mechanistically, elevated copper stress promotes the expression of the desuccinylase SIRT5 while reducing global succinylation in LUAD cells. Furthermore, we found that SIRT5 is a critical mediator of cuproptosis through the desuccinylation modification on ferredoxin1 (FDX1) protein at Lys84. This modification triggers TRIM8-mediated ubiquitination, leading to FDX1 proteasomal degradation and enhanced cuproptosis resistance. These results reveal the important role of SIRT5 in LUAD cuproptosis resistance. Notably, combining the SIRT5 inhibitor MC3482 with the cuproptosis inducer Elesclomol-Cu synergistically suppresses tumor growth in vivo, suggesting a promising therapeutic strategy. These findings elucidate mechanisms underlying cuproptosis resistance and propose a novel treatment approach for LUAD.
2. SARS-CoV-2 ORF3a suppresses host antiviral interferon responses by promoting STUB1-mediated PTEN proteasomal degradation.
The authors identify PTEN as a broad antiviral factor against multiple human coronaviruses and show that SARS‑CoV‑2 ORF3a exploits STUB1 to ubiquitinate and degrade PTEN, blunting interferon responses. Oroxin B, a PTEN agonist, restored antiviral activity in mice, nominating a host-targeted strategy to counter coronavirus immune evasion.
Impact: Revealing a viral protein–host E3 ligase axis that dismantles a host antiviral node (PTEN) provides a mechanistic foundation for PTEN-directed antiviral interventions.
Clinical Implications: While preclinical, PTEN-enhancing strategies (e.g., Oroxin B) could augment innate antiviral defenses, potentially as adjuncts to direct-acting antivirals or in prophylaxis for high‑risk respiratory viral exposures.
Key Findings
- PTEN restricts replication of SARS-CoV-2, HCoV-229E, and HCoV-OC43.
- SARS-CoV-2 ORF3a promotes STUB1-mediated ubiquitination of PTEN at K6, leading to proteasomal degradation and impaired interferon signaling.
- The PTEN agonist Oroxin B enhances antiviral responses in mice.
Methodological Strengths
- Multi-virus assessment and mechanistic mapping of the ORF3a–STUB1–PTEN axis.
- In vivo functional validation of a host-targeted small molecule (Oroxin B).
Limitations
- Lack of human clinical data; translational dosing, safety, and pharmacokinetics of Oroxin B remain to be established.
- Potential virus- and cell-type–specific differences in PTEN modulation require broader validation.
Future Directions: Evaluate PTEN agonists and STUB1/ORF3a inhibitors in primary airway models and animal challenge studies, and define biomarkers of PTEN pathway engagement to inform early-phase clinical development.
UNLABELLED: Human coronaviruses (HCoVs) are a group of RNA viruses characterized by high genetic variability and cross-species transmission potential. They can cause a wide spectrum of respiratory illnesses, ranging from mild upper respiratory tract infections to severe pneumonia, and acute respiratory distress syndrome. PTEN, a well-known tumor suppressor, not only plays a crucial role in tumorigenesis but also enhances antiviral immunity by regulating IRF3 phosphorylation and promoting type I interferon production. In this study, we observed that PTEN significantly inhibited the replication of various HCoVs, including SARS-CoV-2, HCoV-229E, and HCoV-OC43. However, SARS-CoV-2 infection antagonizes the antiviral function of PTEN. Mechanistically, PTEN undergoes ubiquitination at lysine 6, followed by proteasomal degradation after SARS-CoV-2 infection. Through screening, it was found that STUB1 is the key E3 ligase responsible for PTEN degradation under SARS-CoV-2 infection. Furthermore, screening of SARS-CoV-2-encoded proteins revealed that ORF3a promotes STUB1-mediated PTEN ubiquitination and degradation at K6. Previous studies have shown that Oroxin B can exert the effect of a PTEN agonist by upregulating the expression of PTEN. In this study, we demonstrated that Oroxin B significantly enhances antiviral responses in mice. In conclusion, this study reveals the molecular mechanism by which SARS-CoV-2 evades PTEN-mediated antiviral effects, providing new insights for the development of PTEN-targeted antiviral strategies. IMPORTANCE: Human coronaviruses continue to threaten global health, yet how these viruses evade our natural antiviral defenses remains poorly understood. This study reveals that PTEN, a well-known tumor suppressor, also acts as a powerful antiviral molecule capable of limiting multiple human coronaviruses, including SARS-CoV-2. We further show that SARS-CoV-2 dismantles this protection by triggering PTEN degradation through the host enzyme STUB1 and the viral protein ORF3a. This discovery uncovers a previously unknown strategy used by coronaviruses to weaken innate immunity. Importantly, we identify Oroxin B as a promising compound that enhances antiviral responses
3. Multi-Organ Dysfunction in Neonatal Hypoxic Ischemic Encephalopathy and Brain Magnetic Resonance Imaging Outcomes.
Retrospective cohort (N=222) found that multi‑organ dysfunction (MOD) was common among neonates treated with therapeutic hypothermia; greater number of organ dysfunctions—particularly severe neurological or cardiac dysfunction—was strongly associated with HIE-related abnormalities and global injury patterns on brain MRI. Four or more organ dysfunctions conferred markedly higher odds of abnormal MRI (OR 7.44).
Impact: Large single‑center cohort links systemic organ involvement to neuroimaging prognosis after neonatal HIE, informing risk stratification and counseling in neonatal neurocritical care.
Clinical Implications: Count organ dysfunctions when prognosticating neonates after hypoxic‑ischemic injury; patients with ≥4 organ dysfunctions or severe neurologic/cardiac failure warrant heightened surveillance, early neuroimaging, and counseling about higher risk of global brain injury.
Key Findings
- Among 222 neonates treated with therapeutic hypothermia, 40% had HIE-related MRI abnormalities.
- MOD was present in 56% of patients; respiratory dysfunction occurred in 46%, cardiac in 37%, and severe neurological dysfunction in 40%.
- Neonates with four or more organ dysfunctions had markedly higher odds of abnormal brain MRI (OR 7.44; 95% CI 3.51-15.76).
Methodological Strengths
- Relatively large single‑center cohort for neonatal HIE (N=222) with long study period (2008–2022).
- Systematic classification of MRI findings and multivariable logistic regression to quantify associations.
Limitations
- Retrospective single‑center design may limit generalizability and is subject to unmeasured confounding.
- Timing and protocols of MRI and organ dysfunction assessment may have varied across the long study period.
Future Directions: Prospective multicenter validation of MOD‑based prognostic models, integration with continuous physiologic monitoring and standardized MRI timing to refine risk prediction and guide neuroprotective strategies.
BACKGROUND: Neonates with hypoxic-ischemic encephalopathy (HIE) often exhibit multi-organ dysfunction (MOD). We evaluated the association between MOD (defined as involvement of two or more organ systems) and HIE-related brain magnetic resonance imaging (MRI) findings among neonates with neonatal encephalopathy who underwent therapeutic hypothermia. METHODS: Retrospective cohort study of all newborns admitted to the University of Iowa neonatal intensive care unit from January 1, 2008, to June 30, 2022, with encephalopathy who received therapeutic hypothermia. Neonates were classified as having normal or HIE-related changes on MRI. RESULTS: Of 222 newborns, 40% exhibited HIE-related MRI findings. MOD was observed in 56% of all patients. Respiratory issues occurred in 46% of neonates, hepatic and severe neurological dysfunction, defined as seizures or burst suppression in 40%, and cardiac dysfunction in 37%. Severe neonatal encephalopathy was more likely to be associated with MOD. Neonates with HIE changes on MRI were more likely to have MOD than those without (74% vs 45%, P < 0.0001). Neonates with four or more organ dysfunctions had a higher likelihood of abnormal brain MRI (odds ratio = 7.44; 95% confidence interval [CI] 3.51-15.76), and MOD was associated with a greater frequency of global injury on MRI. A logistic regression model showed that the odds ratio for having a brain MRI with HIE findings was 6.63 (95% CI 3.24-13.55, P < 0.0001) with severe neurological dysfunction and 1.95 (95% CI 0.96-3.97, P = 0.065) with cardiac dysfunction. CONCLUSIONS: A greater number of organ dysfunctions in neonates undergoing therapeutic hypothermia is associated with HIE-related changes on brain MRI. The highest risk is observed in patients with severe neurological or cardiac dysfunction.